U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07719530) titled 'Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis' on July 17.
Brief Summary: This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis. The trial includes a 4-week screening period, a 52-week treatment period, and a 12-week safety follow-up period. Approximately 60 patients with psoriasis are expected to participate.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Psoriasisol
Intervention:
DRUG: The SHR-1139 injection
The SHR-1139 injection
DRUG: placebo
...